Targeted cancer therapies based on the inhibition of DNA strand break repair

Oncogene

Volumn 26, Issue 56, 2007, Pages 7816-7824

  O'Connor, M J ^a   Martin, N M B ^a   Smith, G C M ^a  

^a KuDOS Pharmaceuticals Ltd   (United Kingdom)

Author keywords

ATM; CHK1; CHK2; DNA PK; PARP

Indexed keywords

2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 7 HYDROXYSTAUROSPORINE; ABT 888; AG 014699; AZD 2281; AZD 7762; BS 1201; CAFFEINE; CISPLATIN; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ENZYME INHIBITOR; GP 121016; IC 87361; INO 1001; KU 0059436; LY 2603618; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NU 7441; PACLITAXEL; PF 47736; PF 477736; PLATINUM; SU 11752; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VRX 0466617; WORTMANNIN; XL 844;

ACETYLATION; ADENOSINE DIPHOSPHATE RIBOSYLATION; APOPTOSIS; BREAST CANCER; CANCER THERAPY; CATALYSIS; CELL CYCLE; CHEMOSENSITIZATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DNA MODIFICATION; DNA REPAIR; DNA STRAND BREAKAGE; DROSOPHILA; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; EXCISION REPAIR; FANCONI ANEMIA; GENETIC REGULATION; GLIOBLASTOMA; HUMAN; MELANOMA; METASTASIS; MONOTHERAPY; NONHUMAN; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; RNA TRANSLATION; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR CELL; YEAST;

ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; DNA DAMAGE; DNA REPAIR; ENZYME INHIBITORS; HUMANS; NEOPLASMS; PHOSPHORYLATION; RADIATION-SENSITIZING AGENTS; SIGNAL TRANSDUCTION;

ATAXIA TELANGIECTASIA;

EID: 36949012288     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210879     Document Type: Review

References (84)

1. Abraham RT. (2001). Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 15: 2177-2196.
2. Abraham RT. (2004). PI 3-kinase related kinases: 'big' players in stress-induced signaling pathways. DNA Repair (Amst) 3: 883-887.
3. Albertella MR, Green CM, Lehmann AR, O'Connor MJ. (2005a). A role for polymerase eta in the cellular tolerance to cisplatin-induced damage. Cancer Res 65: 9799-9806.
4. Albertella MR, Lau A, O'Connor MJ. (2005b). The overexpression of specialized DNA polymerases in cancer. DNA Repair (Amst) 4: 583-593.
5. Arienti KL, Brunmark A, Axe FU, McClure K, Lee A, Blevitt J et al. (2005). Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J Med Chem 48: 1873-1885.
6. Austen B, Powell JE, Alvi A, Edwards I, Hooper L, Starczynski J et al. (2005). Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with BCLL. Blood 106: 3175-3182.
7. Bartek J, Lukas J. (2003). Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3: 421-429.
8. Bartkova J, Bakkenist CJ, Rajpert-De Meyts E, Skakkebaek NE, Sehested M, Lukas J et al. (2005a). ATM activation in normal human tissues and testicular cancer. Cell Cycle 4: 838-845.
9. Bartkova J, Horejsí Z, Koed K, Krämer A, Tort F, Zieger K et al. (2005b). DNA damage response as a candidate anticancer barrier in early human tumorigenesis. Nature 434: 864-870.
10. Bonicalzi ME, Haince JF, Droit A, Poirier GG. (2005). Regulation of poly(ADP-ribose) metabolism by poly(ADP-ribose) glycohydrolase: where and when? Cell Mol Life Sci 62: 739-750.
11. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E et al. (2005). Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913-917.
12. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S et al. (2004). Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 96: 56-67.
13. Carlessi L, Buscemi G, Larson G, Hong Z, Wu JZ, Delia D. (2007). Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2. Mol Cancer Ther 6: 935-944.
14. Chalmers A, Johnston P, Woodcock M, Joiner M, Marples B. (2004). PARP-1, PARP-2, and the cellular response to low doses of ionizing radiation. Int J Radiat Oncol Biol Phys 58: 410-419.
15. Chappell C, Hanakahi LA, Karimi-Busheri F, Weinfeld M, West SC. (2002). Involvement of human polynucleotide kinase in double-strand break repair by non-homologous end joining. EMBO J 21: 2827-2832.
16. Curtin NJ. (2005). PARP inhibitors for cancer therapy. Expert Rev Mol Med 7: 1-20.
17. D'Amours D, Desnoyers S, D'Silva I, Poirier GG. (1999). Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 342: 249-268.
18. De Murcia JM, Niedergang C, Trucco C, Ricoul M, Dutrillaux B, Mark M et al. (1997). Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci USA 94: 7303-7307.
19. De Soto JA, Wang X, Tominaga Y, Wang RH, Cao L, Qiao W et al. (2006). The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors. Int J Biol Sci 2: 179-185.
20. Durkacz BW, Omidiji O, Gray DA, Shall S. (1980). (ADP-ribose)n participates in DNA excision repair. Nature 283: 593-596.
21. Evans AR, Limp-Foster M, Kelley MR. (2000). Going APE over ref-1. Mutat Res 461: 83-108.
22. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921.
23. Fedier A, Fink D. (2004). Mutations in DNA mismatch repair genes: implications for DNA damage signaling and drug sensitivity (review). Int J Oncol 24: 1039-1047.
24. Fong PC, Spicer J, Reade S, Reid A, Vidal L, Schellens JH et al. (2006). Phase I pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of a small molecule inhibitor of poly ADP-ribose polymerase (PARP), KU-0059436 (Ku) in patients (p) with advanced tumours. J Clin Oncol ASCO Annual Meeting Proceedings Part I 24: A3022.
25. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T et al. (2005). Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434: 907-913.
26. Hardcastle IR, Cockcroft X, Curtin NJ, El-Murr MD, Leahy JJ, Stockley M et al. (2005). Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNAPK) using a small-molecule library approach. J Med Chem 48: 7829-7846.
27. Hartman IV JL, Garvik B, Hartwell L. (2001). Principles for the buffering of genetic variation. Science 291: 1001-1004.
28. Hartwell LH, Weinert TA. (1989). Checkpoints: controls that ensure the order of cell cycle events. Science 246: 629-634.
29. Hay T, Jenkins H, Sansom OJ, Martin NM, Smith GC, Clarke AR. (2005). Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy. Cancer Res 65: 10145-10148.
30. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM et al. (2004). Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 64: 9152-9159.
31. Hoeijmakers JH. (2001). Genome maintenance mechanisms for preventing cancer. Nature 411: 366-374.
32. Hollick JJ, Rigoreau LJ, Cano-Soumillac C, Cockcroft X, Curtin NJ, Frigerio M et al. (2007). Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase. J Med Chem 50: 1958-1972.
33. Hu HY, Horton JK, Gryk MR, Prasad R, Naron JM, Sun DA et al. (2004). Identification of small molecule synthetic inhibitors of DNA polymerase beta by NMR chemical shift mapping. J Biol Chem 279: 39736-39744.
34. Ismail IH, Martensson S, Moshinsky D, Rice A, Tang C, Howlett A et al. (2004). SU11752 inhibits the DNA-dependent protein kinase and DNA double-strand break repair resulting in ionizing radiation sensitization. Oncogene 23: 873-882.
35. Izzard RA, Jackson SP, Smith GC. (1999). Competitive and noncompetitive inhibition of the DNA-dependent protein kinase. Cancer Res 59: 2581-2586.
36. Jackson SP. (2001). Detecting, signalling and repairing DNA double-strand breaks. Biochem Soc Trans 29: 655-661.
37. Janetka JW, Ashwell S, Zabludoff S, Lyne P. (2007). Inhibitors of checkpoint kinases: from discovery to the clinic. Curr Opin Drug Discov Devel 10: 473-486.
38. Jazayeri A, Falck J, Lukas C, Bartek J, Smith GC, Lukas J et al. (2006). ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol 8: 37-45.
39. Jeggo PA. (1998). Identification of genes involved in repair of DNA double-strand breaks in mammalian cells. Radiat Res 150: S80-S91.
40. Kaelin Jr WG. (2005). The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 5: 689-698.
41. Karimi-Busheri F, Rasouli-Nia A, Allalunis-Turner J, Weinfeld M. (2007). Human polynucleotide kinase participates in repair of DNA double-strand breaks by nonhomologous end joining but not homologous recombination. Cancer Res 67: 6619-6625.
42. Kawabe T. (2004). G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 3: 513-519.
43. Kennedy RD, Chen CC, Stuckert P, Archila EM, De la Vega MA, Moreau LA et al. (2007). Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J Clin Invest 117: 1440-1449.
44. Kennedy RD, D'Andrea AD. (2006). DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. J Clin Oncol 24: 3799-3808.
45. Koberle B, Masters JR, Hartley JA, Wood RD. (1999). Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 9: 273-276.
46. Krokan EH, Slupphaug G (eds). (2007). Repair of small base lesions in DNA - from molecular biology to phenotype. DNA Repair 6: 397-560.
47. Kurz EU, Lees-Miller SP. (2004). DNA damage-induced activation of ATM and ATM-dependent signaling pathways. DNA Repair (Amst) 3: 889-900.
48. Lau A, Swinbank KM, Ahmed PS, Taylor DL, Jackson SP, Smith GC et al. (2005). Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase. Nat Cell Biol 7: 493-500.
49. Lavin MF, Kozlov S. (2007). ATM activation and DNA damage response. Cell Cycle 6: 931-942.
50. Lindahl T. (1993). Instability and decay of the primary structure of DNA. Nature 362: 709-715.
51. Liu L, Gerson ST. (2004). Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway. Curr Opin Investig Drugs 5: 623-627.
52. Lucchesi JC. (1968). Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanogaster. Genetics 59: 37-44.
53. Lynch HT, de la Chapelle A. (1999). Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 36: 801-818.
54. Madhusudan S, Smart F, Shrimpton P, Parsons JL, Gardiner L, Houlbrook S et al. (2005). Isolation of a small molecule inhibitor of DNA base excision repair. Nucleic Acids Res 33: 4711-4724.
55. Malkin D, Li FP, Strong LC, Fraumeni Jr JF, Nelson CE, Kim DH et al. (1990). Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233-1238.
56. Masutani M, Nozaki T, Nakamoto K, Nakagama H, Suzuki H, Kusuoka O et al. (2000). The response of Parp knockout mice against DNA damaging agents. Mutat Res 462: 159-166.
57. Matsuoka S, Ballif BA, Smogorzewska A, McDonald III ER, Hurov KE, Luo J et al. (2007). ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316: 1160-1166.
58. McCabe N, Lord CJ, Tutt AN, Martin NM, Smith GC, Ashworth A. (2 005). BR CA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-ribose) polymerase: an issue of potency. Cancer Biol Ther 4: 934-936.
59. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S et al. (2006). Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 66: 8109-8115.
60. Miknyoczki SJ, Jones-Bolin S, Pritchard S, Hunter K, Zhao H, Wan W et al. (2003). Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2: 371-382.
61. Muller C, Christodoulopoulos G, Salles B, Panasci L. ( 1998). DNA-dependent protein kinase activity correlates with clinical and in vitro sensitivity of chronic lymphocytic leukemia lymphocytes to nitrogen mustards. Blood 92: 2213-2219.
62. Nghiem P, Park PK, Kim Y, Vaziri C, Schreiber SL. (2001). ATR inhibition selectively sensitizes G1 checkpoint-deficient cells to lethal premature chromatin condensation. Proc Natl Acad Sci USA 98: 9092-9097.
63. Plummer R. (2005). First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors. J Clin Oncol ASCO Annual Meeting Proceedings 23: A3065.
64. Plummer R. (2006). First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). J Clin Oncol ASCO Annual Meeting Proceedings Part I 24: A8013.
65. Powell SN, DeFrank JS, Connell P, Eogan M, Preffer F, Dombkowski D et al. (1995). Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Res 55: 1643-1648.
66. Ratnam K, Low JA. (2007). Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 13: 1383-1388.
67. Riballo E, Kuhne M, Rief N, Doherty A, Smith GC, Recio MJ et al. (2004). A pathway of double-strand break rejoining dependent upon ATM, Artemis, and proteins locating to gamma-H2AX foci. Mol Cell 16: 715-724.
68. Sarkaria JN, Busby EC, Tibbetts RS, Roos P, Taya Y, Karnitz LM et al. (1999). Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 59: 4375-4382.
69. Sarkaria JN, Tibbetts RS, Busby EC, Kennedy AP, Hill DE, Abraham RT. (1998). Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res 58: 4375-4382.
70. Shimizu N, Sugimoto K, Tang J, Nishi T, Sato I, Hiramoto M et al. (2000). High-performance affinity beads for identifying drug receptors. Nat Biotechnol 18: 877-881.
71. Shinohara ET, Geng L, Tan J, Chen H, Shir Y et al. (2005). DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs. Cancer Res 65: 4987-4992.
72. Shiobara M, Miyazaki M, Ito H, Togawa A, Nakajima N, Nomura F et al. (2001). Enhanced polyadenosine diphosphate-ribosylation in cirrhotic liver and carcinoma tissues in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 16: 338-344.
73. Smith GC, Jackson SP. (1999). The DNA-dependent protein kinase. Genes Dev 13: 916-934.
74. Smith GCM, Jackson SP. (2003) In: Bradshaw RA, Dennis EA (eds). Handbook of Cell Signalling vol.1 Elsevier Science: USA, pp 557-561.
75. Southan GJ, Szabo C. (2003). Poly(ADP-ribose) polymerase inhibitors. Curr Med Chem 10: 321-340.
76. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH. (1990). Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348: 747-749.
77. Stiff T, Walker SA, Cerosaletti K, Goodarzi AA, Petermann E, Concannon P et al. (2006). ATR-dependent phosphorylation and activation of ATM in response to UV treatment or replication fork stalling. EMBO J 25: 5775-5782.
78. Tomoda T, Kurashige T, Moriki T, Yamamoto H, Fujimoto S, Taniguchi T. (1991). Enhanced expression of poly(ADP-ribose) synthetase gene in malignant lymphoma. Am J Hematol 37: 223-227.
79. Virag L, Szabo C. (2002). The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 54: 375-429.
80. Won J, Kim M, Kim N, Ahn JH, Lee WG, Kim SS et al. (2006). Small molecule-based reversible reprogramming of cellular lifespan. Nat Chem Biol 2: 369-374.
81. Yang S, Irani K, Heffron SE, Jurnak F, Meyskens Jr FL. (2005). Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor. Mol Cancer Ther 4: 1923-1935.
82. Yap TA. (2007). First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers. J Clin Oncol ASCO Annual Meeting Proceedings Part I 25: A3529.
83. Zhao Y, Thomas HD, Batey MA, Cowell IG, Richardson CJ, Griffin RJ et al. (2006). Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res 66: 5354-5362.
84. Zou L, Elledge SJ. (2003). Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 300: 1542-1548.